X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs WOCKHARDT LTD. - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES WOCKHARDT LTD. DIVIS LABORATORIES/
WOCKHARDT LTD.
 
P/E (TTM) x 29.0 -15.3 - View Chart
P/BV x 5.0 2.5 199.8% View Chart
Dividend Yield % 1.0 1.3 75.2%  

Financials

 DIVIS LABORATORIES   WOCKHARDT LTD.
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
WOCKHARDT LTD.
Mar-17
DIVIS LABORATORIES/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,2221,129 108.2%   
Low Rs784627 125.0%   
Sales per share (Unadj.) Rs153.1363.1 42.2%  
Earnings per share (Unadj.) Rs39.9-20.4 -195.4%  
Cash flow per share (Unadj.) Rs44.6-7.0 -639.3%  
Dividends per share (Unadj.) Rs10.0010.00 100.0%  
Dividend yield (eoy) %1.01.1 87.5%  
Book value per share (Unadj.) Rs201.8301.8 66.9%  
Shares outstanding (eoy) m265.47110.55 240.1%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x6.62.4 271.0%   
Avg P/E ratio x25.1-42.9 -58.5%  
P/CF ratio (eoy) x22.5-125.9 -17.9%  
Price / Book Value ratio x5.02.9 170.9%  
Dividend payout %25.0-48.9 -51.2%   
Avg Mkt Cap Rs m266,26697,063 274.3%   
No. of employees `0009.76.8 143.8%   
Total wages/salary Rs m4,6879,665 48.5%   
Avg. sales/employee Rs Th4,175.05,931.8 70.4%   
Avg. wages/employee Rs Th481.51,428.1 33.7%   
Avg. net profit/employee Rs Th1,089.3-334.0 -326.2%   
INCOME DATA
Net Sales Rs m40,64340,146 101.2%  
Other income Rs m7491,143 65.5%   
Total revenues Rs m41,39241,289 100.3%   
Gross profit Rs m14,460128 11,297.2%  
Depreciation Rs m1,2331,489 82.8%   
Interest Rs m232,253 1.0%   
Profit before tax Rs m13,953-2,472 -564.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349-211 -1,586.5%   
Profit after tax Rs m10,604-2,260 -469.1%  
Gross profit margin %35.60.3 11,159.0%  
Effective tax rate %24.08.5 281.0%   
Net profit margin %26.1-5.6 -463.4%  
BALANCE SHEET DATA
Current assets Rs m40,10546,160 86.9%   
Current liabilities Rs m6,59519,258 34.2%   
Net working cap to sales %82.567.0 123.0%  
Current ratio x6.12.4 253.7%  
Inventory Days Days119101 117.7%  
Debtors Days Days8194 85.8%  
Net fixed assets Rs m19,99540,165 49.8%   
Share capital Rs m531553 96.1%   
"Free" reserves Rs m53,04332,814 161.6%   
Net worth Rs m53,57433,367 160.6%   
Long term debt Rs m031,903 0.0%   
Total assets Rs m61,58589,687 68.7%  
Interest coverage x618.4-0.1 -636,693.6%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.70.4 147.4%   
Return on assets %17.30 -200,985.2%  
Return on equity %19.8-6.8 -292.2%  
Return on capital %26.1-0.3 -7,782.1%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,3849,121 387.9%   
Fx outflow Rs m10,3992,133 487.5%   
Net fx Rs m24,9856,988 357.6%   
CASH FLOW
From Operations Rs m11,493-2,695 -426.5%  
From Investments Rs m-11,372-6,863 165.7%  
From Financial Activity Rs m-9312,545 -0.7%  
Net Cashflow Rs m283,010 0.9%  

Share Holding

Indian Promoters % 52.0 74.5 69.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 2.3 513.0%  
FIIs % 19.0 7.7 246.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.2 15.4 111.7%  
Shareholders   31,796 67,757 46.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  MERCK LTD  GSK PHARMA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 20, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS